Bristol-Myers' $74B Celgene Buy Gives 2019 M&A Fast Start
Deal-making roared just three days into the New Year as Bristol-Myers Squibb's $74 billion cash-and-stock megadeal for biopharmaceutical company Celgene carried a price tag bigger than last year's largest deal despite...To view the full article, register now.
Already a subscriber? Click here to view full article